Vanella Giuseppe, Dell'Anna Giuseppe, Cosenza Agostino, Pedica Federica, Petrone Maria Chiara, Mariani Alberto, Archibugi Livia, Rossi Gemma, Tacelli Matteo, Zaccari Piera, Leone Roberto, Tamburrino Domenico, Belfiori Giulio, Falconi Massimo, Aldrighetti Luca, Reni Michele, Casadei Gardini Andrea, Doglioni Claudio, Capurso Gabriele, Arcidiacono Paolo Giorgio
Pancreatobiliary Endoscopy and Endosonography Division, IRCCS San Raffaele Scientific Institute, Milan, Italy.
MD Program, Vita-Salute San Raffaele University, Milano, Italy.
Endosc Int Open. 2024 Feb 28;12(2):E297-E306. doi: 10.1055/a-2251-3551. eCollection 2024 Feb.
Besides increasing adequacy, rapid on-site evaluation (ROSE) during endoscopic ultrasound (EUS) or endoscopic retrograde cholangiopancreatography (ERCP) may impact choices and timing of subsequent therapeutic procedures, yet has been unexplored. This was a retrospective evaluation of a prospectively maintained database of a tertiary, academic centre with availability of ROSE and hybrid EUS-ERCP suites. All consecutive patients referred for pathological confirmation of suspected malignancy and jaundice or gastric outlet obstruction (GOO) between Jan-2020 and Sep-2022 were included. Of 541 patients with underlying malignancy, 323 (59.7%) required same-session pathological diagnosis (male: 54.8%; age 70 [interquartile range 63-78]; pancreatic cancer: 76.8%, biliary tract adenocarcinoma 16.1%). ROSE adequacy was 96.6%, higher for EUS versus ERCP. Among 302 patients with jaundice, ERCP-guided stenting was successful in 83.1%, but final drainage was completed in 97.4% thanks to 43 EUS-guided biliary drainage procedures. Twenty-one patients with GOO were treated with 15 EUS-gastroenterostomies and six duodenal stents. All 58 therapeutic EUS procedures occurred after adequate ROSE. With ERCP-guided placement of stents, the use of plastic stents was significantly higher among patients with inadequate ROSE (10/11; 90.9%) versus adequate sampling (14/240; 5.8%) <0.0001; OR 161; 95%CI 19-1352). Median hospital stay for diagnosis and palliation was 3 days (range, 2-7) and median time to chemotherapy was 33 days (range, 24-47). Nearly two-thirds of oncological candidates for endoscopic palliation require contemporary pathological diagnosis. ROSE adequacy allows, since the index procedure, state-of-the-art therapeutics standardly restricted to pathologically confirmed malignancies (e.g. uncovered SEMS or therapeutic EUS), potentially reducing hospitalization and time to oncological treatments.
除了提高诊断准确性外,内镜超声(EUS)或内镜逆行胰胆管造影(ERCP)期间的快速现场评估(ROSE)可能会影响后续治疗程序的选择和时机,但这一点尚未得到充分研究。这是一项对前瞻性维护的数据库进行的回顾性评估,该数据库来自一家拥有ROSE和EUS-ERCP混合设备的三级学术中心。纳入了2020年1月至2022年9月期间所有因疑似恶性肿瘤以及黄疸或胃出口梗阻(GOO)而转诊进行病理确诊的连续患者。在541例潜在恶性肿瘤患者中,323例(59.7%)需要在同一次检查中进行病理诊断(男性:54.8%;年龄70岁[四分位间距63 - 78岁];胰腺癌:76.8%,胆道腺癌16.1%)。ROSE的诊断准确率为96.6%,EUS的准确率高于ERCP。在302例黄疸患者中,ERCP引导下的支架置入成功率为83.1%,但由于43例EUS引导下的胆道引流手术,最终引流完成率达到97.4%。21例GOO患者接受了15例EUS引导下的胃肠吻合术和6例十二指肠支架置入术。所有58例治疗性EUS手术均在ROSE诊断准确后进行。在ERCP引导下置入支架时,ROSE诊断不准确的患者中塑料支架的使用显著高于诊断准确的患者(10/11;90.9%)与诊断准确的患者(14/240;5.8%)相比,P<0.0001;OR 161;95%CI 19 - 1352)。诊断和姑息治疗的中位住院时间为3天(范围2 - 7天),化疗的中位时间为33天(范围24 - 47天)。近三分之二的接受内镜姑息治疗的肿瘤患者需要当代病理诊断。ROSE的诊断准确性使得自首次检查起,原本通常仅限于病理确诊恶性肿瘤的先进治疗方法(如未覆盖的自膨式金属支架或治疗性EUS)得以应用,这可能会减少住院时间和肿瘤治疗的时间。